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Eficacy and safety of the biosimilar ABP 501 
compared with adalimumab in patients with 
moderate to severe rheumatoid arthritis: a 
randomised, double-blind, phase III equivalence study
Stanley Cohen,1 Mark C Genovese,2 Ernest Choy,3 Fernando perez-ruiz,4 
Alan Matsumoto,5 Karel pavelka,6 Jose L pablos,7 Warren rizzo,8 pawel Hrycaj,9 
nan Zhang,10 William Shergy,11 primal Kaur10
ABSTRACT
Objectives ABp 501 is a Food and drug 
Administration-approved biosimilar to adalimumab; 
structural, functional and pharmacokinetic evaluations 
have shown that the two are highly similar. We report 
results from a phase III study comparing eficacy, safety 
and immunogenicity between ABp 501 and adalimumab.
Methods In this randomised, double-blind, active 
comparator-controlled, 26-week equivalence study, 
patients with moderate to severe active rheumatoid 
arthritis (rA) despite methotrexate were randomised 
(1:1) to ABp 501 or adalimumab (40 mg) every 2 
weeks. primary endpoint was risk ratio (rr) of ACr20 
between groups at week 24. primary hypothesis that 
the treatments were equivalent would be conirmed if 
the 90% CI for rr of ACr20 at week 24 fell between 
0.738 and 1.355, demonstrating that ABp 501 is similar 
to adalimumab. Secondary endpoints included disease 
Activity Score 28-joint count-C reactive protein (dAS28-
Crp). Safety was assessed via adverse events (AEs) 
and laboratory evaluations. Antidrug antibodies were 
assessed to determine immunogenicity.
Results A total of 526 patients were randomised 
(n=264, ABp 501; n=262 adalimumab) and 494 
completed the study. ACr20 response at week 24 was 
74.6% (ABp 501) and 72.4% (adalimumab). At week 
24, the rr of ACr20 (90% CI) between groups was 
1.039 (0.954, 1.133), conirming the primary hypothesis. 
Changes from baseline in dAS28-Crp, ACr50 and 
ACr70 were similar. there were no clinically meaningful 
differences in AEs and laboratory abnormalities. A total of 
38.3% (ABp 501) and 38.2% (adalimumab) of patients 
tested positive for binding antidrug antibodies.
Conclusions results from this study demonstrate that 
ABp 501 is similar to adalimumab in clinical eficacy, 
safety and immunogenicity in patients with moderate to 
severe rA.
Trial registration number nCt01970475; results.
INTRODUCTION
Rheumatoid arthritis (RA) is a systemic autoim-
mune disease characterised by synovial inflamma-
tion that results in joint damage. The introduction 
of biologics in 1998 resulted in improvements in 
outcomes with RA treatments.1 Tumour necrosis 
factor (TNF) inhibitors were the first approved 
biological disease-modifying antirheumatic drugs 
(bDMARDs) for treatment of RA, followed by 
additional bDMARDs that had differing mech-
anisms of action.1 The bDMARD adalimumab 
(AbbVie, Chicago, Illinois, USA) is a recombinant 
human IgG
1
 monoclonal antibody that binds specif-
ically to TNF-α. Adalimumab was approved for the 
treatment of moderate to severe RA and has been 
shown to have significant efficacy,2 with improve-
ments in patient’s disease activity, quality of life 
and prevention of structural damage and disability. 
Safety concerns have been well delineated and are 
similar to other biologics, including risk of infec-
tions.2 Adalimumab has been approved for other 
indications, including psoriasis, psoriatic arthritis, 
ankylosing spondylitis, juvenile idiopathic arthritis, 
inflammatory bowel disease, hidradenitis suppu-
rativa and non-infectious intermediate and poste-
rior uveitis and panuveitis; it is one of the most 
frequently prescribed biologics in clinical prac-
tice.2–6 Adalimumab has been extensively studied 
in combination with methotrexate (MTX) and has 
been shown to improve outcomes versus placebo in 
patients with RA who demonstrate an incomplete 
response to MTX.2 7 8
Biosimilars, biological products that are similar 
to an already licensed reference product (such as 
adalimumab), are being developed.9 10 Due to 
complexities involved in developing biological 
proteins, regulatory agencies have developed guide-
lines for demonstrating that proposed biosimilars 
are highly similar to the reference product and that 
no clinically meaningful differences exist between 
the proposed biosimilar and reference product in 
terms of safety, purity and potency.9 11
This pathway differs from innovator biologic 
product development and requires extensive struc-
tural and functional analysis to demonstrate that 
the biosimilar and originator molecule are highly 
similar in structure and effector function. Addi-
tionally, guidelines on biosimilars indicate that 
clinical trials should be conducted to compare the 
biosimilar and reference product in sensitive popu-
lations and with appropriate endpoints to enable 
detection of clinically meaningful differences, if 
any, between the proposed biosimilar and reference 
product.12 13 Using this pathway, several biosim-
ilars such as InflectraTM, RemsimaTM, FlixabiTM 
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(infliximab biosimilars) and BenepaliTM (etanercept biosimilar) 
have received marketing authorisation from the European Medi-
cines Agency (EMA),14–16 and the Food and Drug Administra-
tion (FDA) has recently approved biosimilars of filgrastim (Zarx-
ioTM), infliximab (Inflectra), etanercept (ErelziTM) and adalim-
umab (AMJEVITATM).4 17–20
ABP 501 (AMJEVITA) was approved as the first adalimumab 
biosimilar by the US FDA.21 Analytical and biofunctional eval-
uations have demonstrated that ABP 501 and adalimumab are 
highly similar in their structural and functional properties, as 
well as biological activity.22 23 A phase I, single-dose study of ABP 
501 in healthy adults demonstrated pharmacokinetic equiva-
lence to that of adalimumab.24 To demonstrate similarity in clin-
ical efficacy, safety and immunogenicity of ABP 501 compared 
with adalimumab, two phase III studies were conducted: one 
examined effects in patients with moderate to severe plaque 
psoriasis (NCT01970488) and one in patients with moderate to 
severe RA (NCT01970475).24 25 Here, we report results from a 
phase III study designed to assess the clinical efficacy, safety and 
immunogenicity of ABP 501 compared with adalimumab for the 
treatment of moderate to severe RA.
METHODS
Study design
This was a randomised, double-blind, active comparator-con-
trolled equivalence study designed to show clinical similarity 
between ABP 501 and adalimumab in adalimumab-naive adult 
patients with moderate to severe RA who had an inadequate 
response to MTX. The study was conducted in 12 countries and 
100 centres across Europe, North America and Latin America (see online supplementary table 1). Following screening (≤4 
weeks), patients were randomised 1:1 to receive either ABP 501 
or adalimumab 40 mg subcutaneously on day 1 and then every 
2 weeks until week 22. The primary endpoint assessments were 
conducted at week 24, followed by final safety and immunoge-
nicity assessments at week 26 (see online supplementary methods 
for additional details on methodology and full protocol).
Study populationPatients ≥18 years to ≤80 years of age were included if they 
had a diagnosis of moderate to severe RA (per 2010 American 
College of Rheumatology/European League Against Rheuma-tism criteria) for ≥3 months. Patients were required to have active RA (≥6 swollen joints and ≥6 tender joints) at screening 
and baseline. Patients with an erythrocyte sedimentation rate ≥28 mm/hour or serum C reactive protein (CRP) >1.0 mg/
dL and positivity for rheumatoid factor or anticyclic citrullinated 
peptide at screening were included. Patients were also required 
to have a negative test for tuberculosis at screening, defined as 
a negative purified protein derivative (<5 mm of induration at 
48–72 hours after test) or a negative QuantiFERON (Qiagen, 
Hilden, Germany) test. Patients were required to have received MTX for ≥12 consecutive weeks and were on a stable oral dose of 7.5–25 mg/week for ≥8 weeks before receiving investiga-
tional product (IP). Patients were excluded if they previously used ≥2 biologic therapies for RA or had any previous use of 
adalimumab or an adalimumab biosimilar.
Concomitant therapies
Patients were required to receive a stable dose of MTX for 
the study duration, as prescribed by the treating physician. If 
a patient developed MTX-related side effects, a dose reduc-
tion was possible at the investigator’s discretion. Patients were 
allowed to remain on oral corticosteroids (≤10 mg/day of pred-nisone or equivalent) if on a stable dose for ≥4 weeks prior to 
initiation of IP. Prohibited medications included non-biologic 
DMARDs (other than MTX) and biologic treatment for RA 
other than those being investigated.
Efficacy endpoints
The primary efficacy endpoint was the risk ratio (RR) of 
achieving a 20% improvement from baseline in the American 
College of Rheumatology core set of measurements26 (ACR20) 
at week 24. Secondary efficacy endpoints included assessments 
of Disease Activity Score 28-joint count-CRP (DAS28-CRP), 
the RR for ACR20, ACR50 and ACR70 response (20%, 50%, 
70% improvement in ACR core set of measurements) at various 
time points throughout the study. Additional endpoints included 
the risk differences (RD) for ACR20, ACR50 and ACR70.
Safety
Key safety endpoints included treatment-emergent adverse 
events (TEAEs), serious adverse events (SAEs) and incidence 
of antidrug antibodies (ADAs). Adverse events (AEs) of interest 
were also assessed based on the Standard Medical Dictionary for 
Regulatory Activities (MedDRA) queries.
ADAs were assessed at baseline and weeks 4, 12 and 26. In 
the current study, ADA status was assessed using a highly sensi-
tive and drug tolerant assay based on the Meso Scale Discovery 
Electrochemiluminescent platform,24 27 followed by a two-tiered 
test consisting of a screening and specificity assay. Assays were 
developed for each IP and each serum sample was tested using 
both assays. Of note, these assays differed from the original 
ELISA used for immunogenicity assessments of adalimumab.2 
Samples positive for binding ADAs were tested in a ligand-
binding bioassay for neutralising activity. The sensitivity of the 
ADA detection assay was the same for both adalimumab and 
ABP 501. The assay was validated with a tolerance of 25 µg/mL 
of drug, and the highest observed maximum observed concentra-
tion (C
max
) in this study was <6.0 mg/mL. Drug interference was, 
thus, not expected from the collected samples. The neutralising 
antibody cell-based bioassay was expected to detect all classes 
of antibodies that inhibit the biological activity of the drug, 
including monovalent IgG4 subclass antibodies.24
Statistical analyses
A sample size of approximately 500 patients was chosen to 
achieve 90% power to demonstrate equivalence between the 
ABP 501 and adalimumab groups for the primary efficacy 
endpoint, RR of ACR20 at week 24, with a two-sided signifi-
cance level of 0.05 and equivalence margin of (0.738, 1.355). 
It assumed an expected ACR20 response of 63% at week 24 for 
each group and a 15% dropout by week 24.
All efficacy endpoints were analysed using the full analysis 
set, which included all randomised patients, based on patients’ 
randomised treatment. Randomisation, conducted by an inde-
pendent statistician, was computer-generated and was strati-
fied by geographical region and prior biologic use (with prior 
biologic use capped at 40% of study population) for RA. The 
primary hypothesis, that there were no clinically meaningful 
differences between the ABP 501 and adalimumab groups, 
was tested by comparing the 2-sided 90% confidence interval 
(CI) of the RR of ACR20 at week 24 between ABP 501 and 
adalimumab to the equivalence margin of (0.738, 1.355). The 
rationale for the equivalence margin was based on consid-
erations in the draft US FDA Non-inferiority Clinical Trials 
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Guidance for Industry.28 The equivalence margin of 0.738, 
1/0.738=1.355 for the RR of ACR20 responses was chosen 
based on a published relevant adequate and well-controlled 
trial8 and was expected to preserve 50% of the estimated 80% 
upper confidence bound of the treatment effect of the refer-
ence product compared with placebo. The 90% CI for RR was 
estimated using a generalised linear model adjusted for the 
stratification factors. All other efficacy endpoints, including 
RD of ACR20, were analysed descriptively. For DAS28-CRP, 
treatment differences across time points for change from base-
line in DAS28-CRP were evaluated using a mixed model for 
repeated-measures analysis, with stratification variables, visit, 
treatment group, treatment-by-visit interactions and baseline 
DAS28-CRP included in the model. For ACR50 and ACR70, 
treatment differences were estimated using the same model as 
described above for ACR20. Analyses of the RDs for ACR20, 
ACR50 and ACR70 between ABP 501 and adalimumab were 
descriptive in nature and their corresponding 90% CIs were 
estimated using the generalised linear model adjusted for 
stratification factors. For the primary analysis based on the 
full analysis set, missing values were imputed using the last 
observation carried forward method. As sensitivity analyses, 
efficacy endpoints were also analysed for the per-protocol 
analysis set, which included patients who completed the treat-
ment period and did not have a protocol violation, based on 
observed cases. In addition, for binary endpoints, such as 
ACR20, another imputation was performed for sensitivity in 
which patients with a missing binary response at a certain visit 
were imputed as non-responders.
All safety data were analysed using the safety analysis set (all randomised patients who received ≥1 dose of IP) based on 
patients’ actual treatment received. ADA data were analysed 
using the ADA analysis set, defined as the subset of patients in the safety analysis set who had ≥1 evaluable antibody test result 
(based on actual treatment received).
RESULTS
Patient disposition
A total of 526 patients were randomised and treated with IP 
(ABP 501, n=264; adalimumab, n=262) and 494 (93.9%) 
completed the study (ABP 501, n=243; adalimumab, n=251) 
(figure 1). The main reason for discontinuation in both groups 
was withdrawal of consent (ABP 501, 4.2%, n=11; adalimumab, 
2.3%, n=6).
Baseline demographics and clinical characteristics
The majority of patients were female (81.0%) and white (95.1%), 
with a mean age of 55.9 years (range: 21–80 years) and a mean 
of 9.39 years and median of 7.09 years since diagnosis. Overall, 
baseline demographics and clinical characteristics were similar 
across groups, including mean (standard deviation [SD]) baseline 
DAS28-CRP scores, which were 5.66 (0.92) and 5.68 (0.91) for 
the ABP 501 and adalimumab groups, respectively (table 1).
Concomitant and previous medications
Prior use of biologics for RA and baseline RA medications was 
balanced across groups; the majority of patients (ABP 501, 
73.1%; adalimumab, 71.8%) were treatment-naive for prior use 
of biologics for RA. Oral corticosteroids were used at baseline 
by 50.8% and 49.6% of patients in the ABP 501 and adalim-
umab groups, respectively. Similar percentages of patients used 
non-steroidal anti-inflammatory drugs in each group (ABP 501, 
60.2%; adalimumab, 64.1%). Baseline mean MTX doses were 
similar across treatment groups (ABP 501, 16.89 mg/week; adali-
mumab, 16.56 mg/week).
Clinical efficacy
ACR20
At week 24, 74.6% (194/260) of subjects in the ABP 501 group 
and 72.4% (189/261) of subjects in the adalimumab group met 
the ACR20 response criteria (figure 2A, see online supplemen-
tary tables 2 and 3). The RR (2-sided 90% CI) of ACR20 at week 
24 for ABP 501 versus adalimumab was 1.039 (0.954, 1.133). 
The 90% CI of (0.954, 1.133) was well within the predefined 
equivalence margin (0.738, 1.355), demonstrating clinical equiv-
alence between ABP 501 and adalimumab (figure 2B). Addition-
ally, the RD (two-sided 90% CI) between groups for ACR20 at week 24 was 2.604 (−3.728, 8.936).
The percentage of patients who achieved ACR20 at weeks 2 
and 8 (secondary endpoints) were 35.4% (90/254) of patients 
who took ABP 501 and 24.5% (63/257) of patients who took 
Figure 1 Patient disposition. *n=1 patient took prohibited concomitant medication due to an adverse event and was discontinued from the 
study. First patient was screened on 15 October 2013 and enrolled on 24 October 2013. Patients screened, n=747; per-protocol analysis set, n=463 
(ABP 501, n=230; adalimumab, n=233).
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adalimumab at week 2 and 63.5% (165/260) versus 62.5% 
(163/261) of patients, respectively, at week 8 (figure 2A). The 
percentages of ACR20 responders were comparable across 
groups at all study time points, supporting clinical similarity 
between the ABP 501 and adalimumab groups.
ACR50 and ACR70
The percentages of patients who reached ACR50 response 
criteria at week 24 were 49.2% (120/244) and 52.0% (131/252) 
for the ABP 501 and adalimumab groups, respectively, with a 
RR (90% CI) for ABP 501 versus adalimumab of 0.948 (0.819 , 1.097) and RD (90% CI) of −2.836% (−10.220%, 4.547%). 
The proportion of patients who achieved ACR50 was similar 
across treatment groups throughout the study. A total of 26.0% 
(64/246) and 22.9% (58/253) of patients reached ACR70 
response criteria for ABP 501 and adalimumab at week 24, 
respectively. The RR (90% CI) for ACR70 at week 24 was 1.130 
(0.872, 1.464) and the RD (90% CI) was 3.147% (−3.177%, 
9.470%). The percentages of patients who achieved ACR70 
were also similar across the ABP 501 and adalimumab groups at 
all study weeks.
DAS28-CRP
At week 24, the mean change from baseline in DAS28-CRP was −2.32 for both groups, with a difference between treatment groups (two-sided 90% CI) of −0.01 (−0.18, 0.17), further 
substantiating clinical efficacy equivalence between ABP 501 
and adalimumab. Mean change from baseline in DAS28-CRP 
decreased similarly throughout the study (secondary endpoints) 
in both groups, indicating similar reduced disease activity 
(figure 3).
The percentage of patients who achieved DAS28-CRP remis-
sion increased over time for both groups from weeks 2 to 18 
(range: 6.3%–31.1%, ABP 501; 2.8%–27.1%, adalimumab). At 
week 24, 30.5% and 35.5% of patients in the ABP 501 and adali-
mumab groups, respectively, reached DAS28-CRP remission.
The key efficacy data reported here were also analysed for the 
per-protocol analysis set (patients who completed the treatment 
period and did not have a protocol violation) as sensitivity anal-
yses of key efficacy endpoints. For these endpoints, the per-pro-
tocol analysis set results were similar to that of the full analysis 
set (see online supplementary figure 1), which further confirms 
the similarity between ABP 501 and adalimumab.
Safety
Treatment-emergent adverse eventsOverall, 52.3% of all patients had ≥1 TEAE during the study and 
the percentages of patients who reported TEAEs were similar 
for patients in the ABP 501 and adalimumab groups (50.0% 
and 54.6%, respectively) (table 2). TEAEs reported by >3% of 
patients in either group (ABP 501, adalimumab) were nasophar-
yngitis (6.4%, 7.3%), headache (4.5%, 4.2%), arthralgia (3.0%, 
3.4%), cough (2.7%, 3.1%) and upper respiratory tract infec-
tion (1.5%, 3.8%). There were no differences between groups that were ≥5% for the percentage of patients who experienced 
a TEAE by preferred term. Findings from laboratory evaluations 
and vital sign examinations revealed no clinically significant 
changes in any outcome.
Serious adverse events
A total of 23 (4.4%) patients reported having 27 SAEs throughout 
the study and the percentages of patients were similar between 
the ABP 501 (n=10; 3.8%) and adalimumab (n=13; 5.0%) groups. The only SAE reported for >1 patient was sepsis (n=2; 
ABP 501) and both of these events had resolved by study end. Two patients in the ABP 501 group experienced >1 SAE at the 
same time. One patient had cardiopulmonary failure, pneu-
monia and sepsis and the other experienced peritoneal abscess, 
perforated appendicitis and secondary sepsis. No SAEs or treat-ment-related SAEs occurred in ≥2% of patients for either group 
by preferred term. No deaths occurred in this study.
Adverse events of interest
Standard searches for AEs of interest identified 80 (30.3%) 
patients in the ABP 501 group and 94 (35.9%) patients in the adalimumab group who had ≥1 event of interest (table 2). AEs 
of interest during the study included two malignancies, basal cell 
carcinoma and squamous cell carcinoma, reported in one subject 
in the ABP 501 group and squamous cell carcinoma of the skin 
reported in one subject from the adalimumab group. No cases of 
Table 1 Baseline demographics and clinical characteristics (full 
analysis set)
Variable
ABP 501
(n=264)
Adalimumab
(n=262)
Age, mean (SD), years 55.4 (11.9) 56.3 (11.5)
Women, n (%) 214 (81.1) 212 (80.9)
Race, n (%)
  White 251 (95.1) 249 (95.0)
  Black or African American 9 (3.4) 12 (4.6)
  Asian 3 (1.1) 0 (0.0)
  Other 1 (0.4) 1 (0.4)
Region, n (%)
  Eastern Europe 169 (64.0) 168 (64.1)
  Western Europe 22 (8.3) 20 (7.6)
  North America 72 (27.3) 72 (27.5)
  Latin America 1 (0.4) 2 (0.8)
Duration of RA, mean (SD), years 9.41 (8.08) 9.37 (8.05)
Duration of RA category, n (%)
  <5 years 101 (38.3) 90 (34.4)
  ≥5 years 163 (61.7) 172 (65.6)
Swollen joint count, mean (SD) 14.7 (9.1) 14.1 (8.0)
Tender joint count, mean (SD) 24.3 (14.4) 23.9 (13.5)
Subject Global Health Assessment, mean (SD) 6.5 (1.9) 6.6 (1.9)
Investigator Global Health Assessment, mean 
(SD)
6.8 (1.3) 6.7 (1.6)
HAQ-DI, mean (SD)* 1.482 (0.617) 1.498 (0.647)
Serum CRP, mean (SD), mg/L 13.881 
(20.687)
14.678 
(19.385)
Serum CRP, median, mg/L 6.140 7.630
DAS28-CRP, mean (SD)† 5.66 (0.92) 5.68 (0.91)
RF status, n (%)‡‡
  Positive 243 (92.0) 240 (91.6)
Anti-CCP status, n (%)‡
  Positive 212 (80.3) 230 (87.8)
Prior biologic use for RA, n (%)
  Yes 71 (26.9) 74 (28.2)
MTX dose, mean (SD), mg/week 16.89 (4.81) 16.56 (4.93)
*ABP 501, n=263; adalimumab, n=261; total, n=524. 
†ABP 501, n=264; adalimumab, n=261; total, n=525.
‡At screening.
CCP, cyclic citrullinated peptide; CRP, C reactive protein; DAS28, Disease Activity 
Score 28-joint count; HAQ-DI, Health Assessment Questionnaire-Disability Index; 
MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor.
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active tuberculosis were reported throughout the study. Reported hypersensitivities occurring in >2 patients overall included rash, 
erythematous rash and allergic dermatitis. Liver enzyme elevations 
were reported, however, none led to premature study discontin-
uation and none were associated with increases in bilirubin that 
would cause concern about drug-induced liver injuries according 
to Hy’s law.29 Injection-site reactions occurred in 2.3% and 5.0% 
of patients in the ABP 501 and adalimumab groups, respectively. 
Most events of interest were grade 1 or 2 in severity. Similar 
percentages of patients in the ABP 501 (n=3, 1.1%; infection, 
n=2; hypersensitivity, n=1; heart failure, n=1) and adalimumab 
(n=4, 1.5%; infections, n=3; heart failure, n=1) groups experi-
enced SAEs of interest.
ImmunogenicityAll 526 randomised and treated patients had ≥1 evaluable 
ADA result and were included in the antibody analysis. For 
the ABP 501 and adalimumab groups, 5 (1.9%) and 6 (2.3%) 
patients, respectively, tested positive for pre-existing binding 
antibodies and no patients tested positive for pre-existing 
neutralising antibodies. Overall, 201 (38.2%) patients tested 
positive for binding antibodies at weeks 4, 12, or 26 post-base-
line, which was similar to the percentages in each group (ABP 
Figure 2 (A) Percentage of patients achieving ACR20 by study week (full analysis set). ACR20, 20% improvement from baseline in American College 
of Rheumatology core set measurements. (B) Ratio of ACR responses at week 24. ACR20, 20% improvement from baseline in American College of 
Rheumatology core set measurements. RR, risk ratio; 95% CI 0.938, 1.152.
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501, n=101, 38.3%; adalimumab, n=100, 38.2%) (figure 4A). 
A total of 53 (10.1%) patients tested positive for neutralising 
ADAs at weeks 4, 12, or 26 post-baseline, which was also similar 
to that for each treatment group (ABP 501, n=24, 9.1%; adali-
mumab, n=29, 11.1%).
Descriptive results for ADAs by visit and treatment indicate 
that the incidence of ADAs were similar in patients across both 
groups throughout the course of the study (see online supple-
mentary table 4). In addition, the percentage of patients who 
demonstrated an ACR20 response throughout the study was 
found to be similar across treatment groups regardless of ADA 
status (figure 4B).
Pharmacokinetic results
All 526 randomised patients had at least one evaluable result for 
serum concentration of ABP 501 or adalimumab at any visit and 
were included in the pharmacokinetic analysis. Pharmacokinetic 
results revealed that trough serum concentrations were similar 
between groups across all study weeks, indicating that exposure 
was similar between treatment groups (see online supplementary 
table 5). The geometric mean trough serum concentrations at 
week 24 were 4844.16 ng/mL and 5210.75 ng/mL for ABP 501 
and adalimumab, respectively, with similar concentrations across 
groups at all time points throughout the study (range: ABP 501, 
2062.64–4844.16 ng/mL; adalimumab, 1936.11–5210.75 ng/
mL).
DISCUSSION
Development of biosimilars is a complex process that requires 
demonstration of similar efficacy, safety, immunogenicity and 
pharmacokinetics between the proposed biosimilar and refer-
ence product. For regulatory review, demonstration that there 
are no clinically meaningful differences between the proposed 
biosimilar and its reference product is necessary. FDA guid-
ance on the development and approval of biosimilars requires 
that a stepwise, totality-of-evidence-based approach be used to 
generate data in support of biosimilarity and to evaluate any 
residual uncertainty.13 Likewise, the EMA requires that biosim-
ilars show similarity to the reference product in pharmacoki-
netics, pharmacodynamics, clinical efficacy and safety and that 
a risk management/pharmacovigilance plan is adopted in accor-
dance with EU legislation.12
Analytical comparison has shown that ABP 501 and adali-
mumab are highly similar molecules with respect to physico-
chemical properties22 and biological activity.23 Pharmacoki-
netic equivalence of ABP 501 to adalimumab was also demon-
strated in a phase I, single-dose study conducted in healthy 
adults.24 Results from an additional clinical trial have shown 
that clinical efficacy and safety profiles for ABP 501 are similar 
to those of adalimumab in 350 patients with moderate to 
severe psoriasis (NCT01970488), which adds to the overall 
demonstration of similarity between the biosimilar and refer-
ence product.25
Figure 3 Mean±SD change from baseline in DAS28-CRP by study week (full analysis set). DAS28-CRP, Disease Activity Score 28-joint count-C 
reactive protein.
Table 2 Overall safety and AEs of interest by treatment (safety 
population)
ABP 501
(n=264)
Adalimumab
(n=262)
Number of 
patients, n (%)
Number of 
patients, n (%)
Any TEAE 132 (50.0) 143 (54.6)
Serious AEs 10 (3.8) 13 (5.0)
AEs leading to discontinuation of IP 5 (1.9) 2 (0.8)
AEs leading to study discontinuation 7 (2.7) 2 (0.8)
AEs of interest
  Any 80 (30.3) 94 (35.9)
  Infections 61 (23.1) 68 (26.0)
  Malignancies 1 (0.4) 1 (0.4)
  Hypersensitivity 14 (5.3) 10 (3.8)
  Haematological reactions 5 (1.9) 5 (1.9)
  Heart failure 1 (0.4) 2 (0.8)
  Liver enzyme elevations 13 (4.9) 10 (3.8)
  Injection-site reactions 6 (2.3) 13 (5.0)
For each category, patients were included only once even if they had multiple 
events in that category. AEs coded using MedDRA V.17.1.
AE, adverse event; IP, investigational product; TEAE, treatment-emergent adverse 
event.
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Results from this study indicate that ABP 501 is equivalent 
in efficacy to the reference product, adalimumab, in patients 
with RA. Similar efficacy results were observed for ABP 501 
and adalimumab for ACR20 (primary endpoint), ACR50 and 
ACR70 (secondary endpoints). The mean changes from baseline 
in DAS28-CRP results were also similar between groups at all 
study time points.
The clinical safety results from this study indicate that 
ABP 501 and adalimumab have similar safety profiles. No new 
safety signals were detected in this study compared with other 
adalimumab clinical trials in patients with RA.2 Hypersensitivity 
reactions were reported infrequently and occurred at a generally 
similar frequency in both treatment groups.
Since biosimilars are not identical molecules, the determi-
nation of immunogenicity by ADA formation is a major part of 
the registration programme for approval.2 In the current study, 
a highly sensitive and drug tolerant electrochemiluminescent 
assay was used to assess ADA status.27 In pivotal trials of adali-
mumab in RA, ADA status had been determined by ELISA assays 
that did not allow for detection of ADAs in the presence of drug 
and that measured ADA levels that were much lower than those 
reported in this trial.2 Even though the levels of ADAs detected 
were higher due to a more sensitive assay than those reported from 
historical pivotal trials of adalimumab, the percentages of patients 
who tested positive for binding and neutralising antibodies in this 
trial were similar between the ABP 501 and adalimumab groups 
throughout the study. In a phase I study in which the relationship 
between pharmacokinetics and ADA status was assessed in healthy 
subjects receiving ABP 501 or adalimumab, results showed that 
overall exposure (area under the curve (AUC)) was approximately 
20%–30% lower in subjects who were ADA positive versus those 
who were ADA negative.24 Similarly, the elimination half lives (t
1/2
) 
for ADA positive subjects were shorter (6–7 days) than patients 
who were ADA negative (12–15 days). This inverse correlation 
between ADA levels and serum concentrations of TNFα inhibitors 
has been previously shown in many studies and has been associated 
with decreased clinical efficacy.30 Patients who were symptomatic 
seronegative were not included in this study as they may be misdi-
agnosed as having RA and would introduce more heterogeneity 
within the population. Additionally, as biosimilarity is proven via 
a totality-of-evidence-based approach, the demonstration of simi-
larity between ABP 501 and adalimumab from analytical, func-
tional, pharmacokinetic and clinical perspectives leaves no residual 
uncertainty that ABP 501 will behave differently in patients who 
Figure 4 (A) Immunogenicity at any time point post-baseline throughout the study. (B) ACR20 responders by ADA status throughout the study (full 
analysis set). ACR20, 20% improvement from baseline in American College of Rheumatology core set measurements.
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were seronegative. In the present trial, the clinical responses for 
both ABP 501 and adalimumab were comparable to previously 
reported results suggesting that the majority of the antibodies 
detected in these patients may have little or no clinical relevance.2 
Further, the percentage of patients who achieved an ACR20 
response by ADA status indicates no change in efficacy throughout 
the study for either treatment group, regardless of ADA status.
Limitations of this study include the 6-month trial design; 
however, an open-label extension of this study, up to 72 weeks 
(NCT02114931), is on-going and will provide additional long-
term safety and efficacy data for ABP 501 in patients with 
moderate to severe RA. Moreover, 52-week results from the 
previously mentioned trial in patients with psoriasis will also 
provide insights into the long-term immunogenicity and safety 
profile of ABP 501. Regulatory guidelines for biosimilars do 
not require monitoring of radiographic progression. While this 
may be an area of interest, detecting any clinically meaningful 
differences in radiographic progression would be challenging via 
studies designed to compare two active treatment groups.
Data from this study indicate that the clinical efficacy, safety 
and immunogenicity of ABP 501 are similar to that of adali-
mumab in patients with moderate to severe RA. Additionally, 
analytical, biofunctional and pharmacokinetic properties of 
ABP 501 have previously been shown to be highly similar to 
those of adalimumab.22–24 Taken together, these data contribute 
to the totality-of-evidence-based requirements to demonstrate 
that ABP 501 is similar to adalimumab. The FDA has, thus, 
approved ABP 501 for use as a biosimilar to adalimumab,20 
making it a valuable new therapeutic option for the treatment of 
moderate to severe RA.
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